Please Wait...

SOST // Sclerostin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Scleroteosis is a genetic disorder caused by the loss of the SOST gen product. Studies of this disease characterized, among other clinical features, by progressive bone overgrowth, facial distortion, entrapment of cranial nerves and high intracranial pressure have allowed the identification of the Sclerostin (SOST) protein, which is implicated in the regulation of bone mass (Balemans et al., 2001). SOST is a glycoprotein with a cysteine-knot motif which belongs to the DAN/Cerberus family and is secreted mainly by bone dwelling osteocytes (Veverka et al., 2009). SOST inhibits bone forming activity of osteoblast in vitro, with a mechanism different from the Bone Morphogenetic Protein antagonists (van Bezooijen et al., 2004). Since, SOST have been found to be an endogenous antagonist of the Wnt/β-catenin pathway in the regulation of bone mass (Lin et al., 2009).

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of human SOST in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Greetings from @DrugInfoAssn's DIA China from team @bioclinica : Haibing Xie; Shuang Zhou; Pencheng Ha; Angel Y.; M… https://t.co/m7cDDYEl5U
bioclinica (Yesterday)
Greetings from Beijing where David Kiger discussed the value of #AI in medical imaging along w optimization of EDC/… https://t.co/AJWNmaivpm
bioclinica (Yesterday)
We're hiring recent tech grads in #RTP for #pharma sector! Our innov. clinical financial solution gives our client… https://t.co/GHgOfszO0T
bioclinica (2 days ago)
Great to be @DrugInfoAssn DIA China! Ask us @bioclinica how sponsors & CROs can optimize electronic data capture… https://t.co/TtE4AiLnqY
bioclinica (2 days ago)
RT @bioclinica: Kinks in the clinical supply chain? Check out how one of our clients is using clinical supply optimization technology for m…
bioclinica (2 days ago)
RT @bioclinica: Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen